Table 3.
Comparison of genotype frequencies between the two groups of tacrolimus treated patients and comparison of level/dose ratio of tacrolimus (Tac.) in the genotypes of CYP3A5 and MDR-1
| AA | AG | GG | |
|---|---|---|---|
| CYP3A4 | |||
| <10 ng/ml | 35 | 1 | 0 |
| >10 ng/ml | 8 | 0 | 0 |
| CYP3A5 | AA | AG | GG |
| <10 ng/ml | 1 | 19 | 16 |
| >10 ng/ml | 0 | 0 | 8 |
| MDR-1 | CC | CT | TT |
| <10 ng/ml | 2 | 23 | 11 |
| >10 ng/ml | 0 | 1 | 7 |
| IL-2 | TT | TG | GG |
| <10 ng/ml | 13 | 19 | 4 |
| >10 ng/ml | 3 | 3 | 2 |
| CYP3A5 | |||
| Tac. L/D ratio | AA | AG | GG |
| Median L/D ratio (ng/ml/mg/kg/day) | 2.66 | 6.44 | 8.11 |
| MDR-1 | |||
| Tac. L/D ratio | CC | CT | TT |
| Median L/D ratio (ng/ml/mg/kg/day) | 6.22 | 6.22 | 8.83 |
P = 0.818, NS (Fisher’s exact test); P = 0.010, NS (Fisher’s exact test); P = 0.015, NS (Fisher’s exact test); P = 0.427, NS (Fisher’s exact test); P = 0.011, NS (Kruskal-Wallis ANOVA); P = 0.0122, NS (Kruskal-Wallis ANOVA)